Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Calidi Biotherapeutics, Inc.

Ticker
CLDI
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent developments include leadership appointments, clinical trial progress, partnerships to streamline regulatory submissions, and capital raises through equity offerings.

Recent developments:
  • Calidi Biotherapeutics appointed former Celgene executive Corsee Sander to its board of directors in June 2026 [N1].
  • The company partnered with TransferAI to streamline IND submission for its tumor virotherapy candidate CLD-401 in April 2026 [N2].
  • Calidi released new data on its RedTail mechanism for cancer treatment in April 2026 [N3].
  • In March 2026, Calidi closed a $6 million offering to advance its cancer immunotherapy pipeline [N4].
  • The company reported a 23 percent reduction in net loss for fiscal Q2 in August 2025 [N5].
  • Calidi invited investors to a webinar on precision genetic medicine advances in July 2025 [N6].
  • An agreement was announced in July 2025 for immediate exercise of warrants, anticipating $4.6 million in proceeds [N7].
  • Leadership was strengthened in May 2025 with new CEO and Chief Medical Officer appointments advancing the antitumor virotherapy platform [N8].
Overview

Calidi Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing cancer immunotherapy and antitumor virotherapy treatments. It conducts clinical trials primarily through subsidiaries in Germany and Australia. The company’s pipeline includes candidates such as CLD-401 and CLD-201, with FDA IND clearance obtained for CLD-201. Leadership includes CEO Eric Poma and a board with extensive biotech experience. Calidi has engaged in partnerships to facilitate clinical trial processes and has raised capital through equity offerings to fund its development programs. Financially, the company reported a net loss and maintains liquidity with cash and current assets exceeding current liabilities as of the latest quarter.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy and antitumor virotherapy. The company has reported a net loss of $3.646 million and negative EPS of $1.47 for the quarter ended September 30, 2026. It maintains liquidity with $9.6 million in cash and equivalents (as of December 31, 2024) and a current ratio of 1.27. Recent developments include leadership appointments, clinical trial progress, partnerships to streamline regulatory submissions, and multiple equity offerings to support pipeline advancement.

Scenarios for CLDI

Bull case model:

Calidi’s advancement of its cancer immunotherapy pipeline through clinical trials and regulatory clearances, combined with strategic partnerships and successful capital raises, demonstrate operational progress. The appointment of experienced leadership and board members with biotech backgrounds supports governance and execution capabilities. The company’s liquidity position provides resources to continue development activities. These factors collectively indicate a focused effort to advance its therapeutic candidates and build value in the clinical-stage biotechnology sector.

Bear case model:

Calidi operates with ongoing net losses and negative earnings per share, reflecting the typical financial profile of a clinical-stage biotech without commercial products. The company faces risks related to clinical trial success, regulatory approvals, and the need for continued capital to fund operations. Recent notices of non-compliance with stockholders' equity requirements and share price volatility highlight financial and market risks. The company’s limited revenue and reliance on equity offerings may impact its financial stability and operational continuity.

Moat:

Calidi’s moat is based on its specialized focus on cancer immunotherapy and antitumor virotherapy, leveraging proprietary platforms and clinical-stage assets. Its partnerships and regulatory progress, including FDA IND clearance and collaborations to streamline submissions, contribute to its competitive positioning. The company’s leadership and board bring significant industry experience, supporting strategic development and execution. However, as a clinical-stage biotech, it faces inherent risks related to clinical trial outcomes, regulatory approvals, and capital requirements.

Risks overview
Risks summary
The primary risks for Calidi Biotherapeutics relate to clinical trial and regulatory uncertainties, financial sustainability given ongoing losses and capital needs, and compliance with stock exchange requirements.
Risks details:

• Clinical and Regulatory Risk: The company’s success depends on the outcomes of clinical trials and obtaining regulatory approvals for its therapeutic candidates, which are inherently uncertain.
• Financial and Liquidity Risk: Calidi reports ongoing net losses and relies on equity offerings to fund operations. Maintaining sufficient liquidity is critical to support clinical development and corporate activities.
• Market and Compliance Risk: The company has received notices for non-compliance with stockholders' equity requirements, which may affect its listing status and investor confidence.
• Operational Risk: Operating in multiple jurisdictions exposes the company to foreign currency fluctuations and regulatory complexities, which may impact costs and timelines.

FINAL FORECAST FOR CLDI

Final take one line
Calidi Biotherapeutics is a clinical-stage biotech with detailed disclosures on its cancer immunotherapy pipeline, leadership, and financials, showing active development and capital raises amid typical clinical-stage risks.
Final take 12 to 24 month view

Business trends: Advancement of cancer immunotherapy and virotherapy clinical programs with regulatory clearances and partnerships.
Execution milestones: Leadership strengthening, clinical trial progress, and multiple equity offerings to support pipeline development.
Key risks: Clinical and regulatory uncertainties, financial sustainability amid ongoing losses, and compliance with stock exchange requirements.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on cancer immunotherapy and antitumor virotherapy platforms [S1].
  • The company operates through wholly-owned subsidiaries including StemVac GmbH in Germany and Calidi Biotherapeutics Australia Pty Ltd for clinical trial activities in Australia [S1].
  • Calidi is classified as an emerging growth company and smaller reporting company, with reduced disclosure requirements under the JOBS Act [S1].
  • The company’s leadership includes CEO Eric Poma (appointed April 2025), CFO Andrew Jackson (since October 2023), and Chief Scientific Officer Antonio F. Santidrian (since July 2023) [S1].
  • The board includes experienced directors with backgrounds in biotechnology and healthcare, including former executives from Celgene and other biotech firms [S1].
  • Calidi’s clinical pipeline includes tumor virotherapy candidate CLD-401 and solid tumor treatment candidate CLD-201, with FDA IND clearance received for CLD-201 [N2][S1].
  • The company has engaged in partnerships to streamline IND submissions and clinical trial initiation, including with TransferAI and Avance Clinical in Australia [N2][N4].
  • Recent clinical updates include new data on the RedTail mechanism for cancer treatment and progress in Phase 1 trials for CLD-101 targeting recurrent glioma [N3][S1].
  • Calidi has conducted multiple equity offerings, including a $6 million offering in March 2026 and a $1.2 million offering in September 2026 to advance its immunotherapy pipeline [N4][N1].
  • Financial snapshot as of September 30, 2026, shows cash and equivalents of $9.6 million (as of December 31, 2024), current assets of $4.736 million, current liabilities of $3.726 million, a current ratio of 1.27, and a cash ratio of 2.58 [S2].
  • The company reported a net loss of $3.646 million and basic and diluted EPS of -$1.47 for the quarter ended September 30, 2026 [S2].
  • Calidi’s disclosure controls and procedures were evaluated as effective as of December 31, 2025 [S1].
  • The company has no significant exposure to market risk from interest rates or foreign currency exchange currently but operates in multiple jurisdictions including Europe and Australia [S1].
  • Recent leadership appointments include former Celgene executive Corsee Sander to the board of directors in June 2026 [N1].
Sources
Sources - Context summary

Generated 2026-11-14

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-27 | 10-K
  • S2 | 2026-11-13 | 10-Q
Sources - News headlines
  • N1 | 2026-06-24 | www.nasdaq.com | Calidi Biotherapeutics Appoints Former Celgene Executive Corsee Sander To Board Of Directors | https://www.nasdaq.com/articles/calidi-biotherapeutics-appoints-former-celgene-executive-corsee-sander-board-directors
  • N2 | 2026-04-29 | www.nasdaq.com | Calidi Partners With TransferAI To Streamline IND Submission For Tumor Virotherapy CLD-401 | https://www.nasdaq.com/articles/calidi-partners-transferai-streamline-ind-submission-tumor-virotherapy-cld-401
  • N3 | 2026-04-21 | www.nasdaq.com | Calidi Releases New Data On RedTail Mechanism For Cancer Treatment | https://www.nasdaq.com/articles/calidi-releases-new-data-redtail-mechanism-cancer-treatment
  • N4 | 2026-03-10 | www.nasdaq.com | Calidi Closes $6 Million Offering To Advance Cancer Immunotherapy Pipeline | https://www.nasdaq.com/articles/calidi-closes-6-million-offering-advance-cancer-immunotherapy-pipeline
  • N5 | 2025-08-08 | www.nasdaq.com | Calidi Loss Down 23 Percent in Fiscal Q2 | https://www.nasdaq.com/articles/calidi-loss-down-23-percent-fiscal-q2
  • N6 | 2025-07-22 | www.nasdaq.com | Calidi Biotherapeutics Invites Investors to Webinar on Precision Genetic Medicine Advances | https://www.nasdaq.com/articles/calidi-biotherapeutics-invites-investors-webinar-precision-genetic-medicine-advances
  • N7 | 2025-07-09 | www.nasdaq.com | Calidi Biotherapeutics Announces Agreement for Immediate Exercise of Warrants, Anticipating $4.6 Million in Proceeds | https://www.nasdaq.com/articles/calidi-biotherapeutics-announces-agreement-immediate-exercise-warrants-anticipating-46
  • N8 | 2025-05-14 | www.nasdaq.com | Calidi Biotherapeutics Strengthens Leadership Team and Advances Antitumor Virotherapy Platform with New CEO and Chief Medical Officer Appointments | https://www.nasdaq.com/articles/calidi-biotherapeutics-strengthens-leadership-team-and-advances-antitumor-virotherapy
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine